Myriad Genetics, Inc.
MYGN
$3.84
-$0.27-6.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.38% | 11.21% | 12.15% | 14.78% | 11.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.38% | 11.21% | 12.15% | 14.78% | 11.44% |
| Cost of Revenue | 3.19% | 6.77% | 11.20% | 12.16% | 13.32% |
| Gross Profit | 9.28% | 13.23% | 12.57% | 16.00% | 10.61% |
| SG&A Expenses | -0.07% | -0.16% | -3.10% | -2.68% | -1.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.54% | 4.41% | 2.00% | 2.36% | 3.11% |
| Operating Income | 22.34% | 34.01% | 42.76% | 44.37% | 31.50% |
| Income Before Tax | 46.11% | 52.94% | 58.65% | 40.91% | -41.19% |
| Income Tax Expenses | -2,733.33% | 254.55% | 92.11% | 91.67% | 95.63% |
| Earnings from Continuing Operations | 56.78% | 51.65% | 57.73% | 37.47% | -60.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.78% | 51.65% | 57.73% | 37.47% | -60.47% |
| EBIT | 22.34% | 34.01% | 42.76% | 44.37% | 31.50% |
| EBITDA | 53.14% | 65.32% | 69.74% | 61.17% | 42.61% |
| EPS Basic | 60.45% | 56.19% | 61.33% | 40.77% | -56.55% |
| Normalized Basic EPS | 29.26% | 43.45% | 48.48% | 48.19% | 32.67% |
| EPS Diluted | 60.30% | 56.03% | 61.05% | 40.40% | -56.51% |
| Normalized Diluted EPS | 29.26% | 43.45% | 48.48% | 48.19% | 32.67% |
| Average Basic Shares Outstanding | 7.18% | 9.52% | 9.53% | 7.16% | 4.85% |
| Average Diluted Shares Outstanding | 7.18% | 9.52% | 9.53% | 7.16% | 4.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |